Niagen Bioscience Inc (NAGE) Investor Relations Documents

Niagen Bioscience Inc (NAGE) investor relations documents from the company's IR site: 6 presentations, 34 press releases; latest deck 2026-08-04. Read in-app with summaries. First-party data.

Presentation: Niagen Bioscience reported Q2 2026 net sales of $29.8 million and net income of $1.0 million, maintaining a strong balance sheet with $66.7 million in cash.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-12Press releaseNiagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
2026-08-06Press releaseNiagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Prese
2026-08-04Press releaseNiagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
2026-08-04Earnings deckPresentation
2026-08-03Press releaseNiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
2026-07-28Press releaseNiagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotina
2026-07-27Press releaseNiagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
2026-07-21Press releaseNiagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
2026-07-16Press releaseNiagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
2026-07-15PresentationPresentation Open Event Link, PDF file, July 15, 2026, (opens in new window)
2026-07-15Press releaseNiagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2
2026-07-13Press releaseNiagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orp
2026-07-09Press releaseDownload , Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on
2026-07-08Press releaseNiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
2026-06-11Press releaseNiagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
2026-06-03Press releaseDownload , Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference, June 3, 2026, (opens in
2026-06-02Press releaseNiagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as
2026-05-08Press releaseDownload , Niagen Bioscience Announces Participation in Upcoming Investor Conferences, May 8, 2026, (opens in new window
2026-05-06Press releasePress Release
2026-05-06Fact sheetDownload Our Corporate Fact Sheet
2026-05-06Earnings deckPresentation of Q1 2026, PDF file, (opens in new window)
2026-05-06Press releaseDownload (opens in new window)
2026-05-04Press releaseNiagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
2026-04-28Press releaseDownload , Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™, April 28
2026-04-22Press releaseNiagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
2026-04-09Press releaseDownload , Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chlor
2026-03-31Press releaseDownload , Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting
2026-03-19Press releaseDownload , Niagen Bioscience Increases Share Repurchase Program to $20 Million, March 19, 2026, (opens in new window)
2026-03-18Press releaseDownload , Niagen Bioscience to Present at the 38th Annual ROTH Conference, March 18, 2026, (opens in new window)
2026-03-17Press releaseNiagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing t
2026-03-10Press releaseNiagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru N
2026-03-04Press releaseNiagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 mil
2026-03-04Earnings deckDownload PDF (opens in new window)
2026-02-26Press releaseDownload , Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Busin
2026-02-25Press releaseNiagen Bioscience Secures New U.S. Patent Covering Intravenous and Injection Formulations and Methods of Use for Nicotin
2026-02-20PresentationState of the Science February 2026 (opens in new window)
2026-02-09Press releaseDownload , Niagen Bioscience is the Premiere Sponsor of the Inaugural “NAD for Health: Opportunities & Challenges” Confe
2026-02-06Press releaseDownload , Niagen Bioscience to Report Fourth Quarter and Full Year 2025 Financial Results on Wednesday, March 4, 2026,
2026-01-15Press releaseNiagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
2025-06-09Press releasePress Release

NAGE overview · NAGE earnings · NAGE financials · NAGE KPIs · NAGE ownership · NAGE peers · NAGE filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.